This article is more than 5 years old. Information may no longer be current.
5 recent IBS stories you may have missed
Click Here to Manage Email Alerts
In case you missed it, the editors of Healio Gastroenterology and Liver Disease have compiled a recap of some of our most recent popular articles involving diet and nutrition.
Patients with sucrase- isomaltase deficiency less likely to respond to low-FODMAP diet for IBS-D
Roughly half of patients who go on a low-FODMAP diet to treat diarrhea predominant irritable bowel syndrome do not respond to the change in diet. According to data presented at Digestive Disease Week, many of those patients could have a genetic variant that causes a deficiency of the sucrase-isomaltase enzyme.
Shanti L. Eswaran, MD, of the University of Michigan, said patients with this deficiency, known as SID, have trouble breaking down complex carbohydrates, including sucrose. READ MORE.
Oral FMT with antibiotics does not improve symptoms of IBS-D
Orally delivered fecal microbiota transplantation did not help reduce symptoms in patients with diarrhea-predominant irritable bowel syndrome whether or not they were pre-treated with antibiotics, according to data presented at Digestive Disease Week.
Prashant Singh, MD, of the department of gastroenterology at Beth Israel Deaconess Medical Center, said that gut dysbiosis could be a critical factor in the development of IBS-D, and while FMT treatment for IBS has been the subject of many studies, they have led to conflicting results. READ MORE.
FDA permits marketing of first IBS device for patients 11 to 18 years old
The FDA recently announced that it permitted marketing of the first medical device to help reduce functional abdominal pain for patients aged 11 to 18 years with irritable bowel syndrome when combined with other therapies for the syndrome.
The FDA granted marketing authorization of the IB-Stim to Innovative Health Solutions. READ MORE.
Viberzi controls gut symptoms in patients with IBS-D
Patients with diarrhea-predominant irritable bowel syndrome who previously had an inadequate response to loperamide therapy were able to achieve symptom control with Viberzi, according to data presented at Digestive Disease Week.
“A significant percentage of individuals try or are prescribed over-the-counter loperamide,” Darren M. Brenner, MD, of Northwestern Feinberg School of Medicine, said in his presentation. “I think we’d concede or grant that loperamide will work for improving stool form or stool frequency, but it doesn’t do anything for the gut symptoms of IBS, the abdominal pain, discomfort, bloating and distention.” READ MORE.
FDA issues safety alert on fecal transplants after patient dies
Two adults with weakened immune systems who received investigational fecal microbiota transplantations developed invasive infections caused by extended-spectrum beta-lactamase-producing Escherichia coli, according to an FDA press release.
One of those individuals subsequently died. READ MORE.